The complexity of biologics manufacturing requires a new generation of biopharma software.
A Fundamental Shift
Biopharma Challenges
There has been a fundamental shift in the pharmaceutical industry from chemical compounds to biological processes. Scientists can now use their knowledge of biology to treat some of the most complex, life-threatening conditions. But replicating biological processes has unique challenges, especially when carefully cultivating cells or manipulating a specific RNA sequence.
Software Revolution
There has been a similar revolution in computer science. Software is no longer constrained to running on a single server, but instead allows for parallel processing of huge datasets and increasingly complex algorithms. Developments in artificial intelligence and machine learning have transformed our ability to extract, harmonize, and analyze data.
Fathom’s Innovative Approach
The pharmaceutical industry is creating the future of medicine – and they need access to the critical biomanufacturing data that can optimize their processes and accelerate the development of new therapies. Fathom’s data services provide unprecedented visibility to data which has historically been distributed across a myriad of sources. Our products aggregate, contextualize, and analyze data throughout the manufacturing process to enable real-time visibility and deeper analysis.
Liz Maida is the co-founder and CEO of Fathom. She was previously the co-founder and CEO of Uplevel Security which was acquired by McAfee. Uplevel applied graph theory and machine learning to enhance the efficiency and effectiveness of security operations teams. Prior to Uplevel, Liz served in multiple executive roles at Akamai Technologies leading technology strategy and new product development. She holds a BS from Princeton University and dual MS degrees from MIT. Her graduate school research focused on graph algorithms inspired by biological networks.
Clare Gollnick is the co-founder and CTO of Fathom and was previously the director of data science at NS1, an industry-leading DNS and traffic management platform. An expert on statistical inference and machine learning, Clare writes and speaks often on the intersection of data, philosophy, and entrepreneurship. Clare holds a PhD from Georgia Tech and a BS from UC Berkeley. Clare worked on numerous drug delivery projects during her Ph.D. at Georgia Tech, including using thermostabilized enzymes and humanized antibodies for cancer therapies.
